GLP-1s & incretins · Metabolic & endocrine
An investigational dual amylin and calcitonin receptor agonist that entered a first-in-human Phase 1 safety study in June 2026.
Evidence passport
A one-screen evidence identity for this compound. These fields describe research maturity, confidence and legal status. They are not a safety guarantee, efficacy percentage or recommendation.
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
The 0-100 values rate the strength and maturity of evidence, not how effective or safe the compound is.
Routes recorded
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Evidence for the assessed benefit
Weight loss and comparative tolerability: no qualifying molecule-specific human outcome data.
Human research context: First-in-human Phase 1 initiated; trial registration is not a result.
Research maturity, benefit evidence, safety and approval are different questions.
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
How far human research has progressed: Phase 1 initiated 24 June 2026 (safety, tolerability and pharmacokinetics); no efficacy established
Studied / approved routes
Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.
Discovery
Preclinical
Phase I
Furthest established stage
Phase II
Phase III
Approved
Active early development. Entering Phase 1 means preclinical work supported a first human study, nothing more.
Last documented development: June 2026 — Phase 1 initiation announced by the sponsor
A single peptide designed to activate both the amylin and the calcitonin receptor — the pharmacology often abbreviated DACRA. It works through satiety signalling rather than the incretin (GLP-1) pathway.
What people claim: that dual amylin/calcitonin drugs deliver GLP-1-like weight loss with fewer gastrointestinal effects. What the evidence actually says: this molecule started its first human study in June 2026. A Phase 1 study measures safety, tolerability and drug levels in a small group; no weight, metabolic or comparative outcome is established for it.
Useful next reads based on this compound — not recommendations.
VK2735 evidence profile
An investigational GLP-1/GIP dual agonist in Phase 3 as an injection, with an oral form behind it.
Compare VK3019 vs VK2735 evidence
Same questions, same fields, side by side — including how much human evidence exists.
Claim review: “Tirzepatide improves obstructive sleep apnoea in people with obesity.”
A closely related claim we have graded, from GLP-1s.
GLP-1 Centre
How the incretin medicines compare on trial evidence and where they are actually licensed.
Animal and cell findings are Level 1–2 evidence.
Receptor targets: Amylin receptor, Calcitonin receptor
Mechanism class counts the receptors the pharmacology engages and says whether one molecule or several drugs do it. More targets is not the same as more effective, and none of these labels is a receptor name — there is no GLP-3, GLP-4 or GLP-5 receptor.
This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.
No established human signal
Regulatory decisions apply to specific jurisdictions, products, formulations and indications. An approval elsewhere is not automatically an approval in your country.
Check the regulatory note and linked primary sources for jurisdiction-specific details.
Not approved anywhere. A Phase 1 study evaluates safety, tolerability and how the drug behaves in the body; it is not designed to establish that it works.
Mechanistic rationale or early development without qualifying compound-specific outcome evidence. A registered trial is not a result.
Source transparency
A provenance snapshot of this profile. Counts show what kinds of sources are cited, not how much scientific weight each source deserves.
Review provenance
Registry editorial review: Colin Jackson-White, creator and editor, who is not a doctor or clinician. External specialist review is credited only when a named reviewer has completed a review of this exact profile.
Current linked evidence is sponsor-only. Treat findings as provisional until independent or peer-reviewed documentation is available.
Literature-discovery and AI tools may help locate or challenge candidate evidence, but they are not counted as evidence sources here. Registry judgements are tied to the underlying papers, trial records, regulator documents and official study records.
Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.
These entries record changes to our assessment of the published evidence — not changes to the compound itself.